
FULC Stock Forecast & Price Target
FULC Analyst Ratings
Bulls say
Fulcrum Therapeutics is currently facing challenges with their lead product candidate, pociredir, due to potential risks of secondary malignancies observed with the Polycomb Repressive Complex 2 (PRC2) class. However, the company has a strong pipeline of pre-clinical and clinical-stage programs targeting rare genetic diseases, which could lead to potential future revenue growth. While FULC has not set a timeline for completing their strategic alternatives plan, their experienced management team and focus on epigenetic regulation of gene expression make them a company to watch in the biopharmaceutical industry.
Bears say
Fulcrum Therapeutics is facing significant challenges following the discontinuation of pociredir for the treatment of sickle cell disease. The company is currently undergoing a strategic review to find alternative solutions, but it may be difficult to find a path forward after the FDA's heightened concerns regarding the potential malignancy risks associated with PRC2 inhibition. Additionally, Fulcrum will have to reduce operating expenses to preserve its cash position, which could impact its ability to continue developing its pipeline of products. As such, it may be prudent for investors to have a negative outlook on the company until they can demonstrate a viable path forward and address these challenges.
This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
FULC Analyst Forecast & Price Prediction
Start investing in FULC
Order type
Buy in
Order amount
Est. shares
0 shares